2025 年第 5 期 第 20 卷

钠-葡萄糖协同转运蛋白2抑制剂治疗纤维化疾病的研究进展

Research progress of sodium-glucose transporter protein 2 inhibitors in the treatment of fibrotic diseases

作者：彭璐璐1叶俊松2

英文作者：Peng Lulu1 Ye Junsong2

单位：1赣南医科大学第一附属医院赣南医科大学第一临床医学院，赣州341000；2赣南医科大学第一附属医院干细胞临床转化分中心，赣州341000

英文单位：1The First Clinical Medical College of Gannan Medical University First Affiliated Hospital of Gannan Medical University Ganzhou 341000 China; 2Subcentre for Stem Cell Clinical Translation First Affiliated Hospital of Gannan Medical University Ganzhou 341000 China

关键词：纤维化疾病；钠-葡萄糖协同转运蛋白2抑制剂；达格列净；卡格列净；恩格列净；埃格列净

英文关键词：Fibroticdiseases；Sodium-glucosetransporterprotein2inhibitors；Dapagliflozin；Canagliflozin；Empagliflozin；Ertugliflozin

• 摘要：

• 纤维化是组织反复修复损伤的结果，持续进展可致器官结构破坏和功能减退，乃至脏器衰竭，严重威胁人类健康和生命，但当前的研究尚未找到明确的治愈纤维化疾病的药物及方法。本文总结了钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）缓解纤维化疾病的作用机制以及其在各类器官纤维化中的临床前及临床研究现状。SGLT2i能调节纤维化因子及炎症因子等细胞因子的表达，调控关键的纤维化相关信号通路，发挥显著的抗纤维化效应，并被广泛应用于各类器官纤维化疾病的临床前及临床研究。本文为将SGLT2i应用于纤维化疾病的治疗提供了一定的理论依据。

• Fibrosis is the result of repeated tissue repair and injury, and its continuous progression can lead to organ structure damage and dysfunction, even organ failure, which seriously threatens human health and life. However, current research has not found clear drugs and methods to cure fibrosis. This review summarizes the mechanism of sodium-glucose transporter protein 2 inhibitors (SGLT2i) in alleviating fibrosis diseases and its preclinical and clinical research status in fibrosis of various organs. SGLT2i can regulate the expression of cytokines such as fibrosis factors and inflammatory factors, regulate key fibrosis-related signaling pathways, and exert a significant anti-fibrosis effect. SGLT2i has been widely used in preclinical and clinical studies of fibrotic diseases in various organs. This study provides a theoretical basis for the application of SGLT2i in the treatment of fibrotic diseases.